ES2538702T3 - Análogos de MSH-alfa y MSH-gamma - Google Patents

Análogos de MSH-alfa y MSH-gamma Download PDF

Info

Publication number
ES2538702T3
ES2538702T3 ES13189492.5T ES13189492T ES2538702T3 ES 2538702 T3 ES2538702 T3 ES 2538702T3 ES 13189492 T ES13189492 T ES 13189492T ES 2538702 T3 ES2538702 T3 ES 2538702T3
Authority
ES
Spain
Prior art keywords
lys
peptide
amino acid
case
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13189492.5T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Boesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TXP PHARMA GmbH
Original Assignee
TXP PHARMA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TXP PHARMA GmbH filed Critical TXP PHARMA GmbH
Application granted granted Critical
Publication of ES2538702T3 publication Critical patent/ES2538702T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES13189492.5T 2012-10-19 2013-10-21 Análogos de MSH-alfa y MSH-gamma Active ES2538702T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261716032P 2012-10-19 2012-10-19
US201261716032P 2012-10-19

Publications (1)

Publication Number Publication Date
ES2538702T3 true ES2538702T3 (es) 2015-06-23

Family

ID=49448156

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13189492.5T Active ES2538702T3 (es) 2012-10-19 2013-10-21 Análogos de MSH-alfa y MSH-gamma

Country Status (12)

Country Link
US (3) US9217023B2 (enExample)
EP (2) EP2722340B1 (enExample)
JP (1) JP6429782B2 (enExample)
CN (1) CN104822702B (enExample)
AU (1) AU2013333765B2 (enExample)
CA (1) CA2888277C (enExample)
DK (1) DK2722340T3 (enExample)
ES (1) ES2538702T3 (enExample)
HU (1) HUE025870T2 (enExample)
PL (1) PL2722340T3 (enExample)
RU (1) RU2668791C2 (enExample)
WO (1) WO2014060606A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014060606A1 (en) 2012-10-19 2014-04-24 Txp Pharma Gmbh Alpha- and gamma-msh analogues
WO2015162483A1 (en) * 2014-04-22 2015-10-29 Txp Pharma Gmbh Alpha- and gamma-msh analogues
HUE052977T2 (hu) * 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
WO2016066702A1 (en) * 2014-10-28 2016-05-06 Clinuvel Ag Inflammatory disease
EP3212219A1 (en) * 2014-10-28 2017-09-06 Clinuvel AG New indication for alpha-msh analogues
WO2017068020A1 (en) 2015-10-20 2017-04-27 Txp Pharma Gmbh W-peptide analog
HUE059638T2 (hu) 2019-05-10 2022-12-28 Synact Pharma Aps Ízületi gyulladásos betegségek kombinált kezelése
BR112023002608A2 (pt) 2020-08-12 2023-05-09 Txp Pharma Ag Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade
JP2024522348A (ja) * 2021-05-27 2024-06-18 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ３ｒアゴニストペプチド
IL309102A (en) 2021-06-21 2024-02-01 Synact Pharma Aps Salts and formulations of phenyl pyrrole aminoguanidine
EP4565259A2 (en) * 2022-08-03 2025-06-11 Sightstream Biotherapeutics, Inc. Novel melanocortin analogs
CN117106057B (zh) * 2022-08-19 2024-11-01 南京汉欣医药科技有限公司 一种高纯的人促肾上腺皮质激素或其类似物及其规模化制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5597894A (en) 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
WO1998027113A2 (en) 1996-12-17 1998-06-25 Quadrant Holdings Cambridge Limited Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
WO2002006316A2 (en) 2000-07-14 2002-01-24 Zycos, Inc. Alpha-msh related compounds and methods of use
US8912144B2 (en) 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
ES2663916T3 (es) * 2005-07-08 2018-04-17 Ipsen Pharma Ligandos de los receptores de la melanocortina
ES2407107T3 (es) * 2005-08-26 2013-06-11 Abbvie Inc. Análogos de alfa-MSH terapéuticamente activos
WO2014060606A1 (en) 2012-10-19 2014-04-24 Txp Pharma Gmbh Alpha- and gamma-msh analogues
HUE052977T2 (hu) 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
WO2015162486A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
WO2015162483A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Alpha- and gamma-msh analogues

Also Published As

Publication number Publication date
PL2722340T3 (pl) 2015-08-31
US9486495B2 (en) 2016-11-08
CN104822702B (zh) 2019-07-30
HK1197552A1 (en) 2015-01-23
HUE025870T2 (en) 2016-05-30
AU2013333765B2 (en) 2017-12-07
WO2014060606A1 (en) 2014-04-24
US9951116B2 (en) 2018-04-24
US20170174738A1 (en) 2017-06-22
US20160074469A1 (en) 2016-03-17
US9217023B2 (en) 2015-12-22
RU2668791C2 (ru) 2018-10-02
DK2722340T3 (en) 2015-06-08
EP2944650A1 (en) 2015-11-18
CN104822702A (zh) 2015-08-05
CA2888277C (en) 2023-09-05
CA2888277A1 (en) 2014-04-24
JP6429782B2 (ja) 2018-11-28
EP2722340A1 (en) 2014-04-23
EP2722340B1 (en) 2015-03-04
JP2015534972A (ja) 2015-12-07
BR112015008767A2 (pt) 2017-07-04
RU2015118576A (ru) 2016-12-10
US20140155328A1 (en) 2014-06-05
AU2013333765A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
CN104822702B (zh) α-MSH和γ-MSH类似物
ES2854353T3 (es) Análogos péptidicos con sonda(s) aminoacídicas ramificadas
ES2568063T3 (es) Profármaco de adrenomedulina basado en polietilenglicol y uso del mismo
ES2477880T3 (es) Análogos del glucagón
JP5539310B2 (ja) オキシトシン類似体
ES2407107T3 (es) Análogos de alfa-MSH terapéuticamente activos
ES2430323T3 (es) Construcciones de péptidos natriuréticos cíclicos
AU2006271792A1 (en) Peptides for use in the treatment of obesity
US20150297672A1 (en) Alpha- and gamma-MSH analogues
KR20200010353A (ko) Mic-1 화합물 및 그 용도
US20150376254A1 (en) Gamma-msh analogues
WO2017068020A1 (en) W-peptide analog
EP3986918A1 (en) Adrenomedullin-analogues for long-term stabilization and their use
BR112015008767B1 (pt) Peptídeo, composição farmacêutica e uso do peptídeo
HK1197552B (en) Alpha- and gamma-msh analogues
CN116390938A (zh) 毒蜥外泌肽-4类似物
WO2015019376A1 (en) Synthetic cyclic peptides, agonists and antagonists of urotensin-ii and process for the production thereof